Antiretroviral Choices under the DHHS Guidelines

AIDS Reader

Volumn 14, Issue 2, 2004, Pages 71-74+77

  Boyle, Brian A ^a  

^a Department of Obstetrics Gynecology   (United States)

Author keywords

Antiretroviral therapy; Boosted protease inhibitors; DHHS Guidelines; HIV AIDS

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADOLESCENT; ADULT; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DRUG CHOICE; DRUG CLASSIFICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; DYSLIPIDEMIA; GOVERNMENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; JAUNDICE; LACTIC ACIDOSIS; LIPOATROPHY; LIVER TOXICITY; LOW DRUG DOSE; MONOTHERAPY; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; RASH; REVIEW; SIDE EFFECT; UNITED STATES; VIRUS MUTATION;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; PRACTICE GUIDELINES; UNITED STATES; UNITED STATES DEPT. OF HEALTH AND HUMAN SERVICES;

EID: 1242291883     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. US DHHS. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2003. Available at: http://AIDSinfo.nih.gov/guidelines. Accessed January 16, 2004.
2. US DHHS. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2003. Page 52. Available at: http://AIDSinfo.nih.gov/guidelines.
3. US DHHS. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2003. Page 55. Available at: http://AIDSinfo.nih.gov/guidelines.
4. US DHHS. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2003. Page 3. Available at: http://AIDSinfo.nih.gov/guidelines.
5. US DHHS. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2003. Page 2. Available at: http://AIDSinfo.nih.gov./guidelines.
6. US DHHS. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2003. Page 14. Available at: http://AIDSinfo.nih.gov/guidelines.
7. US DHHS. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2003. Page 17. Available at: http: //AIDSinfo.nih.gov/guidelines.
8. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346:2039-2046.
9. Eron J, Da Silva B, King M, et al. Lopinavir/ritonavir in antiretroviral-naive HIV-infected patients: 5-year follow-up. Presented at the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago. Abstract H-844.
10. Bertz R, Foit C, Ye X, et al. Pharmacokinetics of once-daily vs twice-daily Kaletra (lopinavir/ritonavir) in HIV+ subjects. Presented at the 9th Conference on Retroviruses and Opportunistic Infections; February 24-28,2002; Seattle. Abstract 126.
11. Podzamczer D, Gathe J, Johnson M, et al. Efficacy and safety of once-daily lopinavir/ritonavir vs twice daily lopinavir/ritonavir in antiretroviral-naive patients: 24 week results. Presented at the 9th European AIDS Conference; October 25-29, 2003; Warsaw. Abstract F1/3.
12. Gathe JC, Washington M, Piot D, Mayberry C. Preliminary pilot data on the safety and efficacy of Kaletra (LPV/r) dosed alone for the treatment of HIV in ARV-naive patients: greater than or equal 24 data. Presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago. Abstract H-845.
13. Kempf D, King M, Bauer E, et al. Comparative incidence and temporal accumulation of PI and NRTI resistance in HIV-infected subjects receiving lopinavir/ritonavir or nelfinavir as initial therapy. Presented at the 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston. Abstract 600.
14. Nadler J, Rodriguez-French A, Millard J, Wannamaker P. The NEAT Study: GW433908 efficacy and safety in ART-naive subjects, final 48-week analysis. Presented at the 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston. Abstract 177.
15. Schurman D. Efficacy and safety of GW433908/ritonavir once daily in therapy-naive subjects, 48 week results: the SOLO Study. Presented at the 6th International Congress on Drug Therapy in HIV Infection; November 17-21, 2002; Glasgow, UK. Plenary session 14.4.
16. Squires KE, Thiry A, Giordano M, for the AI424-034 International Study Team. Atazanavir (ATV) QD and efavirenz (EFV) QD with fixed-dose ZDV+3 TC: comparison of antiviral efficacy and safety through wk 24 (AI424-034). Presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2002; San Diego. Abstract H-1076.
17. Sanne I, Cahn P, Percival L, et al. Comparative results (phase II 48-week): BMS-232632, stavudine, lamivudine as HAART for treatment-naive HIV(+) patients (AI424-008). Presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2001; Chicago. Abstract 1-667.
18. Nieto-Cisneros L, Zala C, Fessel WJ, et al. Antiviral efficacy, metabolic changes, and safety of atazanavir (ATV) versus lopinavir/ritonavir (LPV/RTV) in combination with two NRTIs in patients who have experienced virological failure with prior PI-containing regimen(s): 24 week results from BMS AI424-043. Presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment; July 13-16, 2003; Paris. Abstract 117.
19. Badaro R, DeJesus E, Lazzarin A, et al. Atazanavir (ATV) with ritonavir (RTV) or saquinavir (SQV) vs lopinavir/ritonavir (LPV/RTV) in patients with multiple virologic failures: 24-week results from BMS AI424-045. Presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment; July 13-16, 2003; Paris. Abstract 118.
20. US DHHS. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2003. Page 16. Available at: http://AIDSinfo.nih.gov/guidelines.
21. DeJesus E, LaMarca A, Sension M, et al. The Context Study: efficacy and safety of GW433908/RTV in PI-experienced subjects with virologic failure (24 week results). Presented at the 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston. Abstract 178.
22. GlaxoSmithKline. Vertex. Press release: July 28, 2003.
23. US DHHS. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2003. Page 15. Available at: http://AIDSinfo.nih.gov/guidelines.
24. Lyons F, Hopkins S, McGeary A, et al. Nevirapine tolerability in HIV infected women in pregnancy-a word of caution. Presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment; July 13-16, 2003; Paris. Abstract LB27.
25. US DHHS. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2003. Page 18. Available at: http://AIDSinfo.nih.gov/guidelines.
26. US DHHS. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2003. Page 18. Available at: http://AIDSinfo.nih.gov/guidelines.
27. Kearney BP, Mittan A, Sayre JF, et al. Pharmacokinetic drug interaction and long term safety profile of tenofovir DF and lopinavir/ritonavir. Presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago. Abstract A-1617.